Phase I/II dose escalation study of recombinant human interleukin‐11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study*
Mitchell S. Cairo(New York Medical College), Gregory H. Reaman(National Cancer Institute), Susan G. Kreissman(Cancer Institute (WIA)), Stanton Goldman(Gloucestershire Hospitals NHS Foundation Trust), Rita Secola(Children's Hospital of Los Angeles), Stacy L. Berg(Baylor College of Medicine), Carmella van de Ven(Children's Hospital of Orange County), Olga Bessmertny(Columbia University), Joseph Laver(St. Jude Children's Research Hospital), Violet Shen(Ruhr University Bochum), Virginia Davenport(Columbia University)
Cited by 32
Related Papers
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k
Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
|Journal of Clinical Oncology|2008|794
Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
|Cancer Cell|2012|722
Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy
|Journal of neurosurgery|1994|508